Close
Blog & Resources Camargo Blog June 4th, 2009

Melphalan—New 505(b)(2) Orphan Designation

Delcath Systems Inc. announced that the FDA has granted an additional orphan designation for melphalan for the treatment of neuroendocrine tumours metastatic to the liver. Delcath uses a proprietary system they call the Percutaneous Hepatic Perfusion (PHP) System to deliver high doses of existing drugs directly to the site of the tumor. Melphalan was first approved in 1964 in a tablet form under the brand name Alkeran by GSK for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. It was subsequently developed as an injection and approved in 1992 with an orphan indication for systemic administration for palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

This is a great example of taking an older drug, improving it and even getting an orphan indication. This gets 7 years of data exclusivity upon approval.



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
2505 Meridian Parkway
Suite 150
Durham NC, 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights